Guobang Pharma Ltd (605507) - Total Liabilities

Latest as of June 2026: CN¥2.98 Billion CNY ≈ $436.31 Million USD

Based on the latest financial reports, Guobang Pharma Ltd (605507) has total liabilities worth CN¥2.98 Billion CNY (≈ $436.31 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Guobang Pharma Ltd's assets to evaluate the company's liquid asset resilience ratio.

Guobang Pharma Ltd - Total Liabilities Trend (2017–2025)

This chart illustrates how Guobang Pharma Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 605507 current and non-current assets.

Guobang Pharma Ltd Competitors by Total Liabilities

The table below lists competitors of Guobang Pharma Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Beijing Zhong Ke San Huan High-Tech Co Ltd SHE:000970	China	CN¥2.66 Billion
INTERNET IN.JP.ADR 1 ON F:IIJ	Germany	€182.85 Billion
Sapiens International Corporation NV TA:SPNS	Israel	ILA216.50 Million
Shenzhen Hymson Laser Intelligent Equipments Co Ltd SHG:688559	China	CN¥12.61 Billion
Zhejiang Jiuzhou Pharm Co Ltd SHG:603456	China	CN¥1.68 Billion
UroGen Pharma Ltd NASDAQ:URGN	USA	$384.99 Million
Sineng Electric Co Ltd SHE:300827	China	CN¥6.67 Billion
Weifu High-Technology Group Co Ltd SHE:000581	China	CN¥8.98 Billion

Liability Composition Analysis (2017–2025)

This chart breaks down Guobang Pharma Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Guobang Pharma Ltd's balance sheet to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.33	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.35	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.26	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Guobang Pharma Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Guobang Pharma Ltd (2017–2025)

The table below shows the annual total liabilities of Guobang Pharma Ltd from 2017 to 2025.

Year	Total Liabilities	Change
2025-12-31	CN¥2.43 Billion ≈ $355.45 Million	-10.97%
2024-12-31	CN¥2.73 Billion ≈ $399.25 Million	-6.70%
2023-12-31	CN¥2.92 Billion ≈ $427.94 Million	+54.85%
2022-12-31	CN¥1.89 Billion ≈ $276.36 Million	+61.78%
2021-12-31	CN¥1.17 Billion ≈ $170.82 Million	-47.75%
2020-12-31	CN¥2.23 Billion ≈ $326.97 Million	+4.24%
2019-12-31	CN¥2.14 Billion ≈ $313.67 Million	+20.79%
2018-12-31	CN¥1.77 Billion ≈ $259.67 Million	-2.33%
2017-12-31	CN¥1.82 Billion ≈ $265.86 Million	--

About Guobang Pharma Ltd

SHG:605507 China Drug Manufacturers - Specialty & Generic

Market Cap

$2.09 Billion

CN¥14.29 Billion CNY

Market Cap Rank

#6062 Global

#1167 in China

Share Price

CN¥18.26

Change (1 day)

+1.16%

52-Week Range

CN¥14.70 - CN¥29.25

All Time High

CN¥43.71